Clinical Scorecard: Retrospective Analysis of Immune-Related Hepatitis Linked to Pembrolizumab: A Case Report Review

At a Glance

Key Highlights

• Average patient age was 64.2 years, with a higher proportion of older males (source needed).
• Clinical manifestations included liver toxicity, neurological symptoms, and skin reactions (source needed).
• Corticosteroids were the primary treatment for immune-related hepatitis (source needed).
• Onset of hepatitis varied from 2 to 630 days after pembrolizumab initiation (source needed).
• Regular monitoring of liver function is essential during pembrolizumab treatment (source needed).

Guideline-Based Recommendations

Diagnosis

• Evaluate liver function and history of liver disease before initiating pembrolizumab (source needed).

Management

• Corticosteroids are recommended for treatment of immune-related hepatitis (source needed).

Monitoring & Follow-up

• Conduct regular monitoring of liver function during pembrolizumab treatment (source needed).

Risks

• Severe immune-related hepatitis can hinder the clinical application of ICIs (source needed).

Patient & Prescribing Data

42 patients with immune-related hepatitis after pembrolizumab treatment.

Corticosteroids are the mainstay of treatment for managing liver toxicity.

Clinical Best Practices

• Thoroughly assess liver function prior to pembrolizumab therapy (source needed).
• Promptly address any liver function abnormalities during treatment (source needed).

Related Resources & Content

• Case Reports on Pembrolizumab-Induced Hepatitis